U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of Medical Products and Tobacco
  5. Center for Drug Evaluation and Research | CDER
  6. Office of Drug Evaluation I - Division of Neurology Products
  1. Center for Drug Evaluation and Research | CDER

Office of Drug Evaluation I - Division of Neurology Products


The Office of New Drugs is undergoing a reorganization. This site may be updated in the near future. Please check back often. For more information, please visit Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality.

The Division of Neurology Products (DNP) regulates and reviews Investigational New Drug (IND) applications and marketing applications for drug and biologic products for the treatment of neurological diseases and conditions, such as Alzheimer’s disease, stroke, Parkinson’s disease, Huntington’s disease, epilepsy, migraine headaches, muscular dystrophy, amyotrophic lateral sclerosis, multiple sclerosis, dementia, and narcolepsy. 

  • Director: Billy Dunn, M.D.
  • Deputy Director: Eric Bastings, M.D
  • Deputy Director for Safety: Alice Hughes, M.D.
  • Chief, Project Management Staff: Jacqueline Ware, Pharm.D.
  • Safety Regulatory Project Manager: Christine Phipps, Pharm.D.

Contact Us
Mailing Address: 
10903 New Hampshire Avenue, Silver Spring, MD 20993
Building 22, Suite 4346
Phone: (301) 796-2250
Fax: (301) 796-9842